Allergan Inc (AGN)

AGN on New York Consolidated

170.06USD
25 Jul 2014
Price Change (% chg)

$-0.51 (-0.30%)
Prev Close
$170.57
Open
$169.95
Day's High
$170.91
Day's Low
$169.74
Volume
1,335,883
Avg. Vol
3,131,922
52-wk High
$174.49
52-wk Low
$86.95

AGN

Chart for AGN

About

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company’s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye,... (more)

Overall

Beta: 0.76
Market Cap (Mil.): $50,492.59
Shares Outstanding (Mil.): 296.91
Dividend: 0.05
Yield (%): 0.12

Financials

  AGN Industry Sector
P/E (TTM): 38.96 35.64 36.09
EPS (TTM): 4.37 -- --
ROI: 14.59 18.92 18.19
ROE: 21.11 19.68 19.06
Search Stocks

What to Watch in the Week Ahead and on Monday, July 28

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Markets await next week looking for answers to a couple of specific questions: how much did the economy rebound in the second quarter, how strong is the jobs market, and is the Fed going to alter its position at all? With stock markets at a high and

25 Jul 2014

Allergan gets EU recommendation on new use of eye drug

- Allergan Inc, known best for its Botox wrinkle treatment, said on Friday that European Union regulators had recommended use of its eye drug Ozurdex be extended to treat patients with diabetic macular edema.

25 Jul 2014

CORRECTED-Allergan gets EU recommendation on new use of eye drug

(Corrects patient group in third paragraph to remove reference to cataract surgery)

25 Jul 2014

RPT-Republican lawmaker to grill U.S. SEC over Ackman tactics

WASHINGTON, July 24 - A U.S. lawmaker will pressure the U.S. Securities and Exchange Commission on Thursday to consider a raft of reforms, after William Ackman's aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting.

24 Jul 2014

Republican lawmaker to grill U.S. SEC over Ackman tactics

WASHINGTON - A U.S. lawmaker will pressure the U.S. Securities and Exchange Commission on Thursday to consider a raft of reforms, after William Ackman's aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting.

24 Jul 2014

Republican lawmaker to grill U.S. SEC over Ackman tactics

WASHINGTON, July 24 - A U.S. lawmaker will pressure the U.S. Securities and Exchange Commission on Thursday to consider a raft of reforms, after William Ackman's aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting.

24 Jul 2014

Allergan to cut 13 percent of jobs in fight against Valeant

- Allergan Inc, which is fighting a hostile bid from Valeant Pharmaceuticals International Inc, said on Monday it would cut 13 percent of its workforce as part of a restructuring meant to boost profits over the next six years.

21 Jul 2014

UPDATE 3-Allergan to cut 13 percent of jobs in fight against Valeant

July 21 - Allergan Inc, which is fighting a hostile bid from Valeant Pharmaceuticals International Inc , said on Monday it would cut 13 percent of its workforce as part of a restructuring meant to boost profits over the next six years.

21 Jul 2014

Ackman says Valeant-Allergan deal looks closer: CNBC

- Investor William Ackman, who owns nearly 10 percent of Botox maker Allergan Inc , said on Monday that the likelihood of Valeant Pharmaceuticals International Inc succeeding in its hostile takeover for Allergan increased on Monday.

21 Jul 2014

Ackman says Valeant-Allergan deal looks closer-CNBC

July 21 - Investor William Ackman, who owns nearly 10 percent of Botox maker Allergan Inc, said on Monday that the likelihood of Valeant Pharmaceuticals International Inc succeeding in its hostile takeover for Allergan increased on Monday.

21 Jul 2014

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,402 +2.00
SANTEN PHARMACEUTICAL CO., LTD. (4536.T) ¥6,010 +140.00
Lupin Limited (LUPN.NS) Rs1,129.90 +35.50
Nestle SA (NESN.VX) CHF69.25 -0.60
Johnson & Johnson (JNJ.N) $102.11 -0.09
Pfizer Inc. (PFE.N) $30.19 -0.15
Novartis AG (NOVN.VX) CHF79.95 -0.45
High Tech Pharm Co.,Ltd. (106190.KQ) ₩15,450.00 -150.00
Merck & Co., Inc. (MRK.N) $58.15 -0.06
Roche Holding Ltd. (ROG.VX) CHF267.00 -1.20

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks